Etrasimod Receives Strong Recommendation in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults for Induction and Maintenance Phase of Moderately to Severely Active UC
Shanghai, Aug. 15, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that etrasimod (VELSIPITY®) has been included in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults (the "Updated Guidelines"). In patients with moderately to severely active ulcerative colitis (UC),...
CARsgen Therapeutics Announces 2025 Interim Results
SHANGHAI, Aug. 15, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, has announced its 2025 Interim Results. Business Highlights Cash and bank balances were around RMB1,261 million as of June 30, 2025. Cash and cash equivalents and deposits at the...
TraceLink Accelerates Supply Chain Transformation with New OPUS Platform Capabilities for an AI-Powered Future
BOSTON, Aug. 14, 2025 /PRNewswire/ -- TraceLink, the largest end-to-end digital network platform for intelligent orchestration of the life sciences and healthcare supply chain, today announced significant new platform enhancements to drive supply chain transformation with its Orchestration Platform for Universal Solutions (OPUS). The new capabilities are designed to empower supply...
Sisram Medical will Report H1 2025 Financial Results on August 20 and Hold a Conference Call on August 21
H1 2025 conference call to be held on August 21, at 8:30 a.m. Eastern Time HONG KONG, Aug. 14, 2025 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", stock code: 1696.HK; together with its subsidiaries referred to as the "Group"), a global consumer wellness group featuring a first-of-its-kind synergistic ecosystem of business building blocks and consumer-focused brands, including energy-based...
Leads Biolabs Announces Completion of Patient Enrollment in Pivotal Trial of Opamtistomig Monotherapy for Extrapulmonary Neuroendocrine Carcinoma
NANJING, China, Aug. 14, 2025 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced the successful completion of patient enrollment in the ongoing single-arm, pivotal registrational clinical trial (CTR20213023) for Opamtistomig (LBL-024), a novel PD-L1/4-1BB bispecific antibody. This marks the world's first registrational clinical trial evaluating an immunotherapy monotherapy for extrapulmonary neuroendocrine carcinoma...
Clarivate Launches AI-powered Regulatory Assistant Within Cortellis Suite to Boost Productivity and Ease Regulatory Burden
Integrated into Cortellis Regulatory Intelligence, new AI capability helps regulatory teams streamline access to critical intelligence and understand requirements with ease LONDON, Aug. 14, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the beta launch of its AI-powered Regulatory Assistant within Cortellis Regulatory Intelligence. This new capability is designed to help regulatory professionals...
Medulla Expands Global Footprint with Strategic Launch in Singapore
SINGAPORE, Aug. 14, 2025 /PRNewswire/ -- Medulla Communications Pvt. Ltd., one of the world's most awarded healthcare advertising agencies, has announced its expansion into Singapore, establishing a strategic hub to serve the Asia-Pacific region. Known for its expertise in solving healthcare challenges over 15 years, Medulla is looking to create a new super-specialist category as the first digital healthcare advertising...
Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY® by the Taiwan Food and Drug Administration for the Treatment of Moderately to Severely Active Ulcerative Colitis
SHANGHAI, Aug. 14, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the Taiwan Food and Drug Administration (TFDA) has officially accepted the New Drug Application (NDA) for VELSIPITY® (etrasimod) for the treatment of patients with moderately to severely active ulcerative...
Alpha Global partners with LIO to redefine Mental Health Care in Australia
New platform boosts patient experience and safety, reduces clinician burden, and unlocks operational insight across inpatient mental health hospitals SYDNEY, Aug. 14, 2025 /PRNewswire/ -- Alpha Global, a trusted provider of technology-driven solutions for healthcare and care providers in Australia and New Zealand, today announced an exclusive distribution agreement for the...
Shilpa Medicare’s NorUDCA Makes History as First Approved NAFLD Therapy Worldwide
Shilpa Medicare emerges as the global pioneer to receive approval for NorUDCA, offering new hope to over a billion people affected by Non-Alcoholic Fatty Liver Disease (NAFLD) NAFLD affects 1 in 4 people globally (1.2 billion), with 188 million patients in India—most undiagnosed until irreversible damage occurs. A Breakthrough in Liver Health: NorUDCA...
